Company Encyclopedia
View More
name
PMV Pharma
PMVP.US
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc.
1.946 T
PMVP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    PMV Pharmaceuticals (PMVP) Gets a Buy from Oppenheimer

    Oppenheimer's Jeff Jones maintains a Buy rating on PMV Pharmaceuticals with a $6.00 price target. The analyst consensus is a Strong Buy with an average target of $5.00. Jones, who covers the Healthcare sector, has a 3.4% average return and a 42.19% success rate on stock recommendations.

    Tip Ranks·
    US
    PMVP
    -0.78%
    Tip Ranks·
    US
    PMVP
    -0.78%

    PMV Pharmaceuticals (PMVP) Receives a Buy from Craig-Hallum

    Albert Lowe from Craig-Hallum maintains a Buy rating on PMV Pharmaceuticals (PMVP) with a $4.00 price target. Lowe, who covers the Healthcare sector, has an average return of 25.8% and a 56.92% success rate. PMV Pharmaceuticals has a Strong Buy consensus with a $5.00 price target.

    Tip Ranks·
    US
    PMVP
    -0.78%
    Tip Ranks·
    US
    PMVP
    -0.78%

    PMV Pharmaceuticals Reports Increased Quarterly Loss

    PMV Pharmaceuticals, Inc. reported a Q3 net loss of $21.1 million, up from $19.2 million a year earlier. Operating expenses rose to $22.5 million due to increased research and development costs. Despite the losses, the company holds $129.3 million in cash and equivalents, ensuring operational continuity. PMV plans to advance its product candidates through clinical trials, with management confident in their strategic and financial position for ongoing R&D activities.

    Tip Ranks·
    US
    PMVP
    -0.78%
    Tip Ranks·
    US
    PMVP
    -0.78%

    Promising Developments in PMV Pharmaceuticals’ PYNNACLE Phase 2 Trial Boost Buy Rating

    TD Cowen analyst Yaron Werber has maintained a Buy rating on PMV Pharmaceuticals (PMVP) stock, citing promising developments in the PYNNACLE Phase 2 trial for ovarian cancer, which reported a 46% overall response rate and an 8-month median duration of response. The company has a strong financial position with $129 million in cash, supporting potential drug application filings. H.C. Wainwright also reiterated a Buy rating with a $5.00 price target, indicating strong investment potential for PMVP.

    Tip Ranks·
    US
    PMVP
    -0.78%
    Tip Ranks·
    US
    PMVP
    -0.78%

    Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential

    H.C. Wainwright analyst Robert Burns has reaffirmed a Buy rating for PMV Pharmaceuticals, citing stable financials and strategic growth potential. The company's Q3 2025 results showed a net loss per share in line with expectations, supported by a substantial cash reserve projected to last until Q1 2027. PMV's valuation, estimated at $263 million, factors in a 10% approval probability for rezatapopt in solid tumors. Risks include clinical setbacks. Oppenheimer also maintains a Buy rating with a $6.00 price target.

    Tip Ranks·
    US
    PMVP
    -0.78%
    Tip Ranks·
    US
    PMVP
    -0.78%
    © 2025 Longbridge｜Disclaimer